India's high court hears Novartis patent appeal; New Boehringer meds boost sales;

@FiercePharma: Glass Lewis also says Icahn has identified 'several noteworthy issues' about Forest's performance. No problem with Mulligan's other board seats. Follow @FiercePharma

> India's Supreme Court is hearing a final appeal for Glivec patent protection from drugmaker Novartis. Report

> Boehringer Ingelheim reported 2.6% sales growth to €6.4 billion, aided by strong sales of new drugs, including the blood thinner Pradaxa. Article

> The U.K.'s National Health Service has a task force assigned to attack medicine wastage, a problem that costs the country £300 million per year. Report 

> Hungarian drugmaker Egis, which is owned by Laboratoires Servier, says revenue growth will slow next year as domestic regulations put a damper on sales. Item

> India's RPG Life Sciences projects higher sales and profit growth beginning in 2013 as it boost production of bulk drugs and branded generics, and expands into the U.S. News

> Pfizer's massive scale-back at its Sandwich site in U.K. has local leaders saying recovery there could take a decade. Story 

Biotech News

@FierceBiotech: Battery-powered patch delivers drugs for peripheral artery disease. More | Follow @FierceBiotech

@JohnCFierce: Lundbeck plans to slash up to 175 R&D jobs, add more on the sales side, as it adjusts to generic comp. Story | Follow @JohnCFierce

@MaureenFierce: NIH awards GMS Biotech an SBIR grant worth $115,762 to help it develop an array-based blood-screening device. Article | Follow @MaureenFierce

> Paladin makes hostile bid for Afexa. More

> Skyline's Freund slams FDA's tougher stance on drug programs. Details

> As profits surge, Lundbeck slashes R&D staff in Paramus, NJ, and Denmark. Article

> Ironwood hits key milestone with NDA for blockbuster hopeful linaclotide. Report

> Adentrx shares nosedive on FDA rejection, accusations on bungled study. Story

Drug Delivery News

> Multitasking nanoparticles can do biosensing and drug delivery. News

> Professor edits special issue of Advanced Drug Delivery Reviews. Story

> Drug-Delivery company Osmotica to announce expansion near Atlanta. Article

> Self-assembling microrobot for drug delivery? Sure, why not? Details

> Bucky balls can do it all, delivering imaging agents and therapy. More

> Battery-powered patch delivers drugs for peripheral artery disease. Report

Medical Device News

> Stereotaxis sees revenues down, CFO to leave. Story

> Verinata closes $48.5M Series C. News

> TrovaGene regains rights to tech for prenatal testing, cancer. Report

> Magellan launches website, apps to track radiation exposure from imaging. More

And Finally... Psychiatrists fail to properly monitor patients for common side effects of powerful antipsychotic drugs. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.